Antagene
1
61M
1
0.05
- Areas of investment
Summary
Antagene is the famous Corporate Investor, which was founded in 2002. The company was established in Europe in France. The main department of described Corporate Investor is located in the Limonest.
The important activity for fund was in 2019. The fund is generally included in less than 2 deals every year. Deals in the range of 50 - 100 millions dollars are the general things for fund.
The usual cause for the fund is to invest in rounds with 8 partakers. The meaningful sponsors for the fund in investment in the same round are Yuce Biological Technology, Thousand Oaks Biopharmaceuticals, Shenzhen Capital Group.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight MabPlex International. We can highlight the next thriving fund investment areas, such as Non Profit, Association. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.05
- Investments by industry
- Association (1)
- Non Profit (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| MabPlex International | 17 Jan 2019 | Non Profit, Association | Early Stage Venture | 61M | United States, California, Fremont |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.